These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11494442)

  • 1. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
    Jennings PE; Belch JJ
    Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic endothelial dysfunction: effect of free radical scavenging in Type 2 diabetic patients.
    De Mattia G; Laurenti O; Fava D
    J Diabetes Complications; 2003; 17(2 Suppl):30-5. PubMed ID: 12623166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
    Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
    Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: clinical assessment.
    Jennings PE; Scott NA; Saniabadi AR; Belch JJ
    Metabolism; 1992 May; 41(5 Suppl 1):36-9. PubMed ID: 1574014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
    Wascher TC; Boes U
    Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
    Bilinska M; Potocka J; Korzeniowska-Kubacka I; Piotrowicz R
    Coron Artery Dis; 2007 Sep; 18(6):455-62. PubMed ID: 17700217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: an ESR study.
    Noda Y; Mori A; Packer L
    Res Commun Mol Pathol Pharmacol; 1997 May; 96(2):115-24. PubMed ID: 9226746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
    Chen LL; Yu F; Zeng TS; Liao YF; Li YM; Ding HC
    Eur J Pharmacol; 2011 Jun; 659(2-3):296-301. PubMed ID: 21453695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects.
    Formoso G; De Filippis EA; Michetti N; Di Fulvio P; Pandolfi A; Bucciarelli T; Ciabattoni G; Nicolucci A; Davì G; Consoli A
    Diabetes Metab Res Rev; 2008; 24(3):231-7. PubMed ID: 17966969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphonylureas and cancer: a case-control study.
    Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
    Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
    Stefanović V; Antić S; Mitić-Zlatković M; Stojiljković S; Milojković M; Bogicević M; Vlahović P
    Ann Clin Biochem; 2003 May; 40(Pt 3):232-4. PubMed ID: 12803833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of sulfonylurea and sulfonylurea-benfluorex therapy in patients with type 2 diabetes treated with commercial sulfonylurea-biguanide combinations].
    Di Cianni G; Benzi L; Ciccarone AM; Cecchetti P; Giannarelli R; Penno G; Navalesi R
    Clin Ter; 1990 Aug 15-31; 134(3-4):187-91. PubMed ID: 2147619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular benefits of gliclazide beyond glycemic control.
    Jennings PE
    Metabolism; 2000 Oct; 49(10 Suppl 2):17-20. PubMed ID: 11078471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.